-
公开(公告)号：US08679499B2
公开(公告)日：2014-03-25
申请号：US12697882
申请日：2010-02-01
IPC分类号： A61K39/395 , A61P37/08 , A61P11/06 , A61K31/7032
CPC分类号： A61K31/164 , A61K31/19 , A61K31/70 , A61K31/7024 , A61K31/7028
摘要： Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
摘要翻译： 与NKT细胞抗原受体和其对应的抗原呈递分子相互作用，但抑制NKT细胞免疫功能的分子被施用于患者。 特别感兴趣的病症包括治疗系统性红斑狼疮（SLE），癌症，动脉粥样硬化和过敏性疾病。 在本发明的一些实施方案中，所述抑制剂是抗过敏糖脂，例如β-半乳糖神经酰胺。 提供了这种糖脂的药物制剂，并且可用于治疗涉及不期望的NKT细胞活化的疾病。
-
2.发明授权Method of converting a Th2-type allergic immune response into a Th1-type immune response 失效将Th2型过敏免疫反应转化为Th1型免疫应答的方法
公开(公告)号：US6086898A
公开(公告)日：2000-07-11
申请号：US339068
申请日：1999-06-23
IPC分类号： A61K45/00 , A61K38/00 , A61K39/00 , A61K39/35 , A61K39/36 , A61K39/38 , A61K39/39 , A61K39/395 , A61P11/06 , A61P29/00 , A61P37/02 , A61P37/08 , A61P43/00
CPC分类号： A61K39/39 , A61K39/35 , A61K2039/55594 , A61K2039/57
摘要： Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and/or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is a Listeria adjuvant.
摘要翻译： 提供了用于治疗与由抗原特异性T细胞过度产生Th2型细胞因子相关的过敏性和其它免疫疾病的方法。 如本发明提供的用佐剂进行免疫治疗极大地抑制气道高反应性和气道炎症的发展。 这种免疫治疗显示可逆转正在进行的气道疾病，并将过敏性炎症反应转化为保护性免疫应答。 特别感兴趣的条件包括与产生Th2细胞因子和/或IgE抗体相关的过敏症状，哮喘，过敏性鼻炎和过敏反应。 佐剂的添加诱导Th1型免疫应答，并可将已建立的Th2型应答重定向至所选抗原的Th1型应答。 优选地，减少抗原特异性IgE产生而不改变抗原特异性增殖反应的强度。 根据本发明使用的一种特别优选的佐剂是利斯特氏菌佐剂。
-
公开(公告)号：US20110300154A1
公开(公告)日：2011-12-08
申请号：US12674191
申请日：2008-08-21
申请人： Dale T. Umetsu , Muriel Pichavant , Rosemarie Helena DeKruyff-Umetsu , Everett Hurteau Meyer , Stephanie Ann Shore
发明人： Dale T. Umetsu , Muriel Pichavant , Rosemarie Helena DeKruyff-Umetsu , Everett Hurteau Meyer , Stephanie Ann Shore
IPC分类号： A61K39/395 , A61K31/7088 , A61P11/06 , A61K31/7028 , A61P37/06 , A61K38/17 , A61K31/713
CPC分类号： A61K38/1793 , A61K31/00 , C12N15/1136 , C12N2310/11 , C12N2310/14 , A61K2300/00
摘要： The invention provides strategies for treating and preventing airway hyperreactivity and non-allergic asthma comprising antagonizing IL-17 activity and/or production by iNKT cells. Provided herein is a method of diagnosing non-allergic asthma and airway hyperreactivity comprising neutrophils quantification in sputum.
摘要翻译： 本发明提供治疗和预防气道高反应性和非过敏性哮喘的策略，其包括拮抗IL-17活性和/或由iNKT细胞产生。 本文提供了一种诊断非过敏性哮喘和气道高反应性的方法，其包括痰中的嗜中性粒细胞定量。
-
公开(公告)号：US07553939B2
公开(公告)日：2009-06-30
申请号：US10188012
申请日：2002-07-01
申请人： Jennifer Jones McIntire , Rosemarie Dekruyff , Dale T. Umetsu , Gordon J. Freeman , Vijay Kuchroo
发明人： Jennifer Jones McIntire , Rosemarie Dekruyff , Dale T. Umetsu , Gordon J. Freeman , Vijay Kuchroo
CPC分类号： C07K14/70503
摘要： A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.
摘要翻译： 提供了与调节免疫功能和细胞存活相关的遗传基因座和相应的蛋白质家族。 这些基因编码具有保守IgV和粘蛋白结构域的细胞表面分子。 包含TIM家族的基因座与遗传上与免疫功能障碍有关，包括哮喘。 此外，TIM基因家族位于人类染色体5的区域，通常在恶性肿瘤和骨髓增生异常综合征中缺失。 基因序列中的多态性与气道高反应性和过敏性炎症的发生以及IL-4和IL-13的T细胞产生有关。 蛋白质包括人类甲型肝炎细胞受体hHAVcr-1。
-
公开(公告)号：US20180105547A1
公开(公告)日：2018-04-19
申请号：US15603425
申请日：2017-05-23
CPC分类号： C07H15/24 , A61K31/56 , A61K31/70 , A61K31/704 , A61K35/15 , A61K35/17 , A61K2039/572 , A61K2300/00
摘要： The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pretreatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.
-
公开(公告)号：US07682614B2
公开(公告)日：2010-03-23
申请号：US11266033
申请日：2005-11-02
IPC分类号： A61K31/7028 , A61K39/395
CPC分类号： A61K31/164 , A61K31/19 , A61K31/70 , A61K31/7024 , A61K31/7028
摘要： Molecules that interact with the NKT cell antigen receptor and its counterpart antigen presenting molecule, but which inhibit the NKT cell immune function, are administered to a patient. Conditions of particular interest include the treatment of systemic lupus erythematosus (SLE), cancer, atherosclerosis, and allergic disease. In some embodiment of the invention, the inhibitory agent is an anergizing glycolipid, for example β-galactosylceramide. Pharmaceutical formulations of such glycolipids are provided, and find use in the treatment of diseases involving undesirable NKT cell activation.
摘要翻译： 与NKT细胞抗原受体和其对应的抗原呈递分子相互作用，但抑制NKT细胞免疫功能的分子被施用于患者。 特别感兴趣的病症包括治疗系统性红斑狼疮（SLE），癌症，动脉粥样硬化和过敏性疾病。 在本发明的一些实施方案中，所述抑制剂是抗过敏糖脂，例如β-半乳糖神经酰胺。 提供了这种糖脂的药物制剂，并且可用于治疗涉及不期望的NKT细胞活化的疾病。
-
公开(公告)号：US20180207273A1
公开(公告)日：2018-07-26
申请号：US15747326
申请日：2016-07-28
申请人： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu , Novartis AG , DANA-FARBER CANCER INSTITUTE, INC. , Children's Medical Center Corporation
发明人： Glenn Dranoff , Catherine Anne Sabatos-Peyton , Barbara Brannetti , Alan S. Harris , Thomas Huber , Thomas Pietzonka , Jennifer Marie Mataraza , Walter A. Blattler , Daniel J. Hicklin , Maximiliano Vasquez , Rosemarie H. DeKruyff , Dale T. Umetsu , Gordon James Freeman , Tiancen Hu , John A. Taraszka , Fangmin Xu
IPC分类号： A61K39/395 , A61K45/06 , A61P35/00
CPC分类号： A61K39/39566 , A61K39/00 , A61K39/3955 , A61K45/06 , A61K2039/507 , A61P35/00 , C07K16/2803 , C07K2299/00 , C07K2317/24 , C07K2317/34 , C07K2317/76 , C07K2317/94 , A61K2300/00
摘要： Combination therapies comprising antibody molecules that specifically bind to TIM-3 are disclosed. The combination therapies can be used to treat or prevent cancerous or infectious conditions and disorders.
-
公开(公告)号：US09657046B2
公开(公告)日：2017-05-23
申请号：US13699436
申请日：2011-05-24
CPC分类号： C07H15/24 , A61K31/56 , A61K31/70 , A61K31/704 , A61K35/15 , A61K35/17 , A61K2039/572 , A61K2300/00
摘要： The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.
-
9.发明申请MODULATION OF TIM RECEPTOR ACTIVITY IN COMBINATION WITH CYTOREDUCTIVE THERAPY 有权TIM受体活性与细胞因子治疗组合的调节作用公开(公告)号：US20120156224A1
公开(公告)日：2012-06-21
申请号：US13176651
申请日：2011-07-05
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/30 , A61K39/0011 , C07K14/70503 , C07K2317/75
摘要： A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.
摘要翻译： 提供了与调节免疫功能和细胞存活相关的遗传基因座和相应的蛋白质家族。 这些基因编码具有保守IgV和粘蛋白结构域的细胞表面分子。 包含TIM家族的基因座与遗传上与免疫功能障碍有关，包括哮喘。 此外，TIM基因家族位于人类染色体5的区域，通常在恶性肿瘤和骨髓增生异常综合征中缺失。 基因序列中的多态性与气道高反应性和过敏性炎症的发生以及IL-4和IL-13的T细胞产生有关。 蛋白质包括人类甲型肝炎细胞受体hHAVcr-1。
-
公开(公告)号：US07214380B1
公开(公告)日：2007-05-08
申请号：US09561089
申请日：2000-04-28
CPC分类号： A61K39/39 , A61K39/35 , A61K2039/55594 , A61K2039/57
摘要： Methods are provided for the treatment of allergic and other immune disorders associated with overproduction of Th2 type cytokines by antigen specific T cells. Immunotherapy with adjuvants, as provided in the present invention, greatly inhibits the development of airway hyperreactivity and airway inflammation. Such immunotherapy is shown to reverse ongoing airway disease, and convert allergic inflammatory responses into protective immune responses. Conditions of particular interest include allergic conditions associated with production of Th2 cytokines and/or IgE antibodies, asthma, allergic rhinitis, and anaphylactic reactions. The addition of adjuvant induces a Th1-type immune response and can redirect an established Th2-type response to a Th1-type response for the selected antigen. Preferably, antigen-specific IgE production is reduced without altering the intensity of the antigen-specific proliferative response. One particularly preferred adjuvant for use in accordance with the present invention is a Listeria adjuvant.
摘要翻译： 提供了用于治疗与由抗原特异性T细胞过度产生Th2型细胞因子相关的过敏性和其它免疫疾病的方法。 如本发明提供的用佐剂进行免疫治疗极大地抑制气道高反应性和气道炎症的发展。 这种免疫治疗显示可逆转正在进行的气道疾病，并将过敏性炎症反应转化为保护性免疫应答。 特别感兴趣的条件包括与产生Th2细胞因子和/或IgE抗体相关的过敏症状，哮喘，过敏性鼻炎和过敏反应。 佐剂的添加诱导Th1型免疫应答，并可将已建立的Th2型应答重定向至所选抗原的Th1型应答。 优选地，减少抗原特异性IgE产生而不改变抗原特异性增殖反应的强度。 根据本发明使用的一种特别优选的佐剂是利斯特氏菌佐剂。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.031 秒)
